The Global ProstateCancer Therapeutics Market, by drug type (Hormonal Therapy, Anti-androgens,Immunotherapy, Targeted Therapy, and Chemotherapy) and by distribution channel(Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) was valued atUS$ 8,738.2 million in 2017 and is projected to exhibit a CAGR of 7.4% over theforecast period (2017–2025).
Prostate cancer is a serioushealth issue among men and has a large socioeconomic impact on the society. In2017, the American Cancer Society estimated around 161,360 new diagnoses ofprostate cancer in the U.S., leading to 26,730 fatalities. The most commonsites for prostate cancer to metastasize are the seminal vesicles, the lymphnodes, the lungs, and various bones around the hips and the pelvic region. Thevarious treatment for these new tumor is expected to create highly lucrativegrowth scenario for the prostate cancer therapeutics market.
Furthermore, research,development and approval of new therapies by companies is also contributing tothe growth of prostate cancer therapeutics. For instance, Eligard developed byTolmar Pharmaceuticals, Inc. is marketed in the U.S., Australia, and NewZealand by Tolmar, and by the following partners in the remaining territories:Astellas (Europe, Asia, and MENA), Sanofi (Canada), Key Oncologics (SouthAfrica) and HanAll (South Korea) for the palliative treatment of advancedprostate cancer. These key developments in the prostate cancer therapeuticsenable to change the market dynamics over a given period of forecast forefficient treatment.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1257
Browse 29 Market Data Tables and33 Figures spread through 160 Pages and in-depth TOC on "Prostate CancerTherapeutics Market, by Drug Type (Hormonal Therapy, Anti-androgens,Immunotherapy, Targeted Therapy, and Chemotherapy) and By Distribution Channel(Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) - GlobalForecast to 2025".
The complexity of the treatmentof prostate cancer at different stages has influenced the medical industry toestablish clinical evidences for novel therapies and significantly increasetheir influence to capture the untapped potential of prostate cancertherapeutics market, functioning as a key development opportunity that will propelthe market growth. Presently, Sipuleucel-T, brand name Provenge (made byDendreon Corporation) is an immune cell based vaccine, the only vaccineavailable which has resulted in increased overall survival inhormone-refractory prostate cancer patients. Increase in the prevalence ofprostate cancer and robust development of biosimilars by manufacturers toensure affordable treatment to the patients is also a major factor to drivegrowth of the prostate cancer therapeutics market.
As per data published by theWorld Cancer Research Fund International, over 1.1 million cases of prostatecancer were reported worldwide in 2012, which accounts for around 8% of thetotal tumor cases. Approvals of Zytiga and Xtandi in 2013 and 2014,respectively, for the first-line treatment of metastatic castration-resistantprostate cancer patients in Europe and the U.S., and for the treatment ofdocetaxel-resistant patients in Japan, has contributed to the increase in salesof both products. However, many of the drugs indicated for use innon-metastatic patients, or prescribed in combination with already-costlytherapies in metastatic castration-resistant patients, are unaffordable forpatients in emerging economies and also in developed economies (for uninsuredpatients). High cost of therapy hinders the preference for biologics, deterringthe market growth in terms of revenue.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/prostate-cancer-therapeutics-market-1257
In Canada, Prostate CancerFoundation of Canada supports research, cure, and prevention of prostate cancerthrough an online portal. This portal provides detailed information regardingsymptoms, diagnosis, and commercially available treatment options. Such portalsoffer free access of the services from prostate cancer support groups throughmonthly peer meetings, special educational events, community health fairs andmore to people all around the world, which is resulting in growth of the prostatecancer therapeutics market.
Key takeaways of the ProstateCancer Therapeutics Market:
The global prostate cancertherapeutics market is expected to expand at a CAGR of 7.4% during the forecastperiod (2017–2025) as there exists a largely untapped and highly lucrativemarket especially in Asia Pacific, Latin America, Middle East and Africa.
Hormone Therapy is widelypreferred, as it helps to shrink the prostate and any cancer that has spread,and makes the treatment more effective
Hospital Pharmacies is the majordistribution channel of prostate cancer therapeutics that drives the growthowing to it being the primary care center for prostate cancer
Some of the major playersinvolved in global prostate cancer therapeutics market are Johnson &Johnson, Astella, Inc, Sanofi-Aventis, Bayer AG, AstraZeneca Plc, Pfizer Inc.,Dendreon Corporation (Sanpower Group Co. Ltd.), Ipsen Group, Tolmar PharmaceuticalsInc, Endo Pharmaceuticals, AbbVie, Inc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1257
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollar opportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
